Blood tests called liquid biopsies for cancer screening, monitoring and treatment
https://www.facingourrisk.org/XRAY/liquid-biopsies-for-cancer-screening-monitoring-treatment
Full article: https://www.annalsofoncology.org/article/S0923-7534(21)02046-9/fulltext
Could a simple blood test change cancer detection, treatment and monitoring? Several companies are offering a type of blood test known as a liquid biopsy to detect multiple cancers at their earliest stages, monitor response to treatment and help choose the best treatment. Although progress has been made using liquid biopsies to treat cancer, these tests have not yet been shown to detect cancer early enough to save lives. (posted 9/29/21)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- How do I know if I’m at high risk for cancer?
- I’m at high risk for cancer; what types of screenings should I have and when?
- I’ve completed treatment; should I have a liquid biopsy to monitor for recurrence?
- My cancer has recurred. Should I consider a liquid biopsy to determine the best treatment?
- What are the risks and benefits of having a liquid biopsy?
Open Clinical Trials
The following research studies are looking at liquid biopsy and cancer.
- NCT04962529 Breast cancer liquid biopsy trial. This study looks at whether a liquid biopsy test being developed is a less-invasive alternative to a tissue biopsy in patients with suspected metastatic breast cancer.
- NCT04567420: DNA-Guided Second Line Adjuvant Therapy For High-Residual Risk, Stage II-III, Hormone Receptor-Positive, HER2-Negative Breast Cancer. This study monitors people with early-stage, high-risk breast cancer for possible recurrence using a test called circulating tumor DNA (ctDNA). People who test positive for ctDNA but who have no other signs of recurrence, receive either the drugs palbociclib combined with fulvestrant or standard-of-care adjuvant hormone therapy.
- NCT03568630 Blood markers of early pancreas cancer. This study attempts to identify markers of early pancreatic cancer for screening individuals who are at higher-than-average risk.
- Validating a blood test for early ovarian cancer detection in high-risk women and families: microRNA detection study (MiDE). The MiDe study looks at whether a liquid biopsy can accurately detect early-stage ovarian cancer in women who are at high risk due to an inherited mutation.
Visit our Featured Research Page and Research Search and Enroll Tool to find additional studies enrolling people with or at high risk for cancer.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.